SUECARLA ADAMS: Open Payments
NPI 1093360166 · TAMPA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,055 in 163 payments from 14 companies in 2025. Trend: 2023 $2,901 · 2024 $2,596 · 2025 $3,055
Food & beverage: $2,832Education: $223
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 46 | $754 |
| Alkermes, Inc. | 22 | $451 |
| ABBVIE INC. | 16 | $360 |
| Otsuka America Pharmaceutical, Inc. | 26 | $302 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 17 | $288 |
| Axsome Therapeutics, Inc. | 8 | $200 |
| E.R. Squibb & Sons, L.L.C. | 7 | $188 |
| Neurocrine BioSciences, Inc. | 5 | $148 |
| Lundbeck LLC | 5 | $122 |
| Janssen Pharmaceuticals, Inc | 3 | $78 |
Products named: REXULTI, VRAYLAR, AUSTEDO XR, CAPLYTA, ARISTADA, UZEDY, Auvelity, COBENFY.
Industry payments across FL — which companies pay providers there.
